## Supplementary information

## A pipeline for complete characterization of complex germline rearrangements from long DNA reads

Satomi Mitsuhashi ${ }^{1 \#}$, Sachiko Ohori ${ }^{1 \#,}$ Kazutaka Katoh ${ }^{2,3}$, Martin C Frith ${ }^{3-5,{ }^{*}}$, Naomichi Matsumoto ${ }^{1 *}$

1. Department of Human Genetics, Yokohama City University Graduate School of Medicine 2. Research Institute for Microbial Diseases, Osaka University, Suita, Japan
2. Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST)
3. Graduate School of Frontier Sciences, University of Tokyo
4. Computational Bio Big-Data Open Innovation Laboratory (CBBD-OIL), AIST \# Contributed equally

To whom correspondence should be addressed:
Martin C Frith, PhD
Artificial Intelligence Research Center
National Institute of Advanced Industrial Science and Technology (AIST)
2-3-26 Aomi, Koto-ku, Tokyo, 135-0064, Japan
Telephone: +81-3-3599-8001
Fax: +81-3-5530-2061
E-mail: mcfrith@edu.k.u-tokyo.ac.jp

Naomichi Matsumoto, MD, PhD
Department of Human Genetics
Yokohama City University Graduate School of Medicine
Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan
Telephone: +81-45-787-2606
Fax: +81-45-786-5219
E-mail: naomat@yokohama-cu.ac.jp

## Ancestral genome

Here, we clarify the concept of "ancestral reference genome" mentioned in the main text. An ancestral human genome sequence could be constructed in the following way. For each known genetic variant (e.g. an inversion) in the extant human population, determine which allele is ancestral (e.g. by comparison to ape genomes), and put that allele in the reference. Note that the genome constructed in this way may never have existed.

No doubt, this construction cannot be perfectly finished, especially in genome regions with complex recent rearrangements. Nevertheless, ancestral alleles could be determined in many simple cases, and this would already be useful.

For example, consider a deletion variant, where an ancestrally-present 1 kb segment is deleted in some extant genomes. It is useful for this segment to be present in the reference genome. If it is absent, analysis of genomes where the segment is present is difficult: in particular, the segment may be incorrectly compared to paralogous parts of the reference.

The reader may wonder about the converse situation: a 1 kb insertion, which was ancestrally absent. Here, it is important to consider that deletions and insertions are not entirely symmetric. Deletion of large, non-repetitive segments is usual. On the other hand, insertion of a large non-repetitive segment, not derived from any ancestral segment, is unusual. Typically, sequences are descended from ancestral sequences, rather than appearing de novo. Thus, a large "insertion" is more likely to be a duplication or translocation, for example of a transposable element. Analysis of such sequence changes is tractable, for example the retrotransposon integrations characterized in this study.

There is certainly room for debate about the practical merits of an ancestral reference, but the idea at least merits consideration.

## Supplementary Methods

## Clinical details of the patients

## Patient 1

Detailed clinical information was described elsewhere [1, 2]. Briefly, the patient was a Caucasian female. She was 40 years old at the time of the previous study. She was delivered at 37 weeks of gestation with a birth weight of $2,930 \mathrm{~g}$. She presented with amenorrhea at age 17. Primary ovarian failure was indicated by hormonal level and her hypoplastic uterus with bilateral streak gonads were found by laparotomy. G-banded chromosomal analysis showed a balanced reciprocal translocation 46X, t(X;2) (q22;p13). Array CGH analysis using the Agilent $4 \times 44 \mathrm{~K}$ oligo array platform at a resolution of 44 K showed no deletions at the breakpoint. She was taller than other members of her family ( $177 \mathrm{~cm}, 98^{\text {th }}$ tile). She got pregnant by in vitro fertilization with egg donation at the age of 36 years. She underwent parathyroidectomy at 24-week gestation due to primary hypoparathyroidism.

## Patient 2

Detailed clinical information was described elsewhere [2]. Briefly, the patient was a female born to non-consanguineous Japanese parents and was 38 years old at the time of the previous study. She was born with neonatal asphyxia. She had her first menstrual period once at 14 years old, but then became amenorrheic and started on hormonal replacement therapy. She was diagnosed with primary hyperthyroidism at the age of 18 years and underwent subtotal thyroidectomy and started thyroid hormonal therapy. G-banded chromosomal analysis showed a balanced reciprocal translocation 46X, t(X;4)(q21.3;p15.2) at the age of 38 years.

## Patient 3

Detailed clinical information was described elsewhere [3]. Briefly, the patient was a girl to non-consanguineous Japanese parents and was 9 years old at the time of the previous
study. She had no family with SHFM. She was delivered at 38 weeks of gestation after an uneventful pregnancy with a birth weight of $2,850 \mathrm{~g}(-0.02 \mathrm{SD})$, length of $48 \mathrm{~cm}(-0.4 \mathrm{SD})$, and occipitofrontal circumference of $32 \mathrm{~cm}(-0.5 S D)$. She was admitted to a hospital for weak sucking when she was one month old. She showed cutaneous syndactyly of $4^{\text {th }}$ and $5^{\text {th }}$ digits of the right foot and $1^{\text {st }}, 2^{\text {nd }}, 4^{\text {th }}$ and $5^{\text {th }}$ digits of the left foot. Her hands were normal. In addition, she had strabismus, micrognathia, full lower lip, bilateral ear canal stenosis, a severe mixed type deafness, and developmental disorder. She walked alone at 21 months. Her developmental stage at 25 months was equal to $7-8$ months. Since 3 years of age, selfinjuries, hyperactivity, and sleep disorders appeared.

## Patient 4

Detailed clinical information was described elsewhere [4]. Briefly, the patient was a girl to non-consanguineous Japanese parents and was 5 years old at the time of the previous study. She was delivered at term without asphyxia after an uneventful pregnancy. She started clonic convulsions of extremities 2 days after birth. She was diagnosed with WEST syndrome at 5 months of age. She had intellectual disability without head control, series of tonic-spasms, and hypsarrhythmia on Electroencephalogram.

## dnarrange details

As stated in the main text, dnarrange performs these three steps:

1. Discard any patient read that has any two rearranged fragments in common with any control read.
2. Discard any patient single read that has any rearrangement not shared by any other patient read. More precisely: discard any patient read that has a pair of consecutive rearranged fragments not shared by any other patient read.
3. Group patient reads that cover the same rearrangement. Discard groups with fewer than $s$ reads. (In this study, $s=3$.)
dnarrange assumes that it is given read-to-genome alignments with this property, which is
guaranteed by last-split: each read base is aligned to at most one genome base. In other words, the alignments indicate the unique source, in the assumed-ancestral reference genome, of each part of the read.

In detail, dnarrange performs these steps:

1. In order to recognize large "deletions" as rearrangements, if an alignment has deletions $>=g$ (a threshold; default 10kb), split it into separate alignments either side of these deletions.
2. Get rearranged reads. We classify rearrangements into four types (Additional file 1: Fig. S1): inter-chromosome, inter-strand (if a read's alignment jumps between the two strands of a chromosome), non-colinear (if a read's alignment jumps backwards on the chromosome), and "big gap" (if a read's alignment jumps forwards on the chromosome by $>=g$ ). The reason for excluding gaps $<g$ is simply that we wish to focus on complex rearrangements rather than simple deletions.
3. Discard any patient single read that shares a rearrangement with any control read. The precise criteria for "shares a rearrangement" are in the next subsection.
4. Discard any patient read with any rearrangement not shared by any other patient read (precise criteria below). Repeat this step until no further reads are discarded (so that dnarrange has the useful property of idempotence).
5. Group patient reads that share rearrangements. First, a link is made between any pair of reads that share a rearrangement. Then, groups are connected components, i.e. sets of reads linked directly or indirectly.
6. Discard groups with fewer than $s$ reads.

## Definition of two reads sharing a rearrangement

Two reads $R$ and $S$ (Additional file 1: Fig. S2) are deemed to share a rearrangement if:

1. The alignments of $R$ to the genome include two alignments $A$ and $B$, and the alignments of $S$ include $X$ and $Y$, such that:
2. $A$ overlaps $X$ in the genome.
3. $B$ overlaps $Y$ in the genome.
4. $A$ and $B$ exhibit one of the four rearrangement types (inter-chromosome, inter-strand, non-colinear, or big gap), and $X$ and $Y$ exhibit the same rearrangement type.
5. If the rearrangement type is non-colinear (jumps backwards in the chromosome) or big gap (jumps forwards in the chromosome):
6. The chromosome range jumped between $A$ and $B$ overlaps the range jumped between $X$ and $Y$.
7. The number of chromosome bases jumped between $A$ and $B$ is $<=2 x$ that between $X$ and $Y$, and vice-versa.
8. The alignments have consistent strandedness. Strandedness means: which chromosome strand the read aligns to. "Consistent" means that either: $A$ and $X$ have the same strandedness and so do $B$ and $Y$, or: $A$ and $X$ have opposite strandedness and so do $B$ and $Y$.
9. The alignments' order in their reads is consistent with the strandedness. If the alignments have the same strandedness they must occur in the same order in their reads, else they must occur in the opposite order.
10. The number of bases in read $R$ between $A$ and $B$ is close to the number of bases in read $S$ between $X$ and $Y$. Specifically: abs $(s-r+m-n)<=d$ (default 1000), where $s, r$, $m$, and $n$ are defined in Additional file 1: Fig. S2.

## Discarding any read with any rearrangement not shared by another read

For each read: check each pair of alignments $(A$ and $B)$ that occur consecutively in the read and exhibit one of the four rearrangement types (Additional file 1: Fig. S2). Require that this rearrangement is shared (as defined above) by a pair of alignments $(X$ and $Y$ ) that occur consecutively in another read.

Miscellaneous dnarrange details

Two alignments are considered to be on different chromosomes only if the chromosomes are known to be different. E.g. "chr7" and "chrUn" are not known to be different, but "chr7" and "chr5_random" are. The non-colinear rearrangement type is not considered for chrM, which is circular. Two alignments $A$ and $B$ of read $R$ are not deemed to exhibit a "big gap" if any other alignment is between them in read $R$ (Additional file 1: Fig. S2).

## Limitations of dnarrange

1. It may have trouble finding patient-specific rearrangements that are close to rearrangements shared with controls. This is because, if a patient read shares a rearrangement with a control read, the patient read is discarded.
2. It will not work well with extremely long reads, or assembled chromosomes. This is because it starts by seeking reads that contain patient-specific rearrangements and lack rearrangements shared with controls. It may work best with a mixture of shorter reads (to separate nearby rearrangements) and longer reads (to span huge repeats, and know the order and orientation of rearranged fragments unambiguously).
3. It is not really designed to find transposable element insertions. If two reads overlap the same TE insertion, they may get aligned to different source TEs in the genome, because this alignment is highly ambiguous. Then dnarrange will not consider these reads to share a rearrangement, so will not group them. This could be fixed by loosening the criteria for sharing a rearrangement, at a risk of retaining many artefactual rearrangements (e.g. Additional file 1: Fig. S3).

## dnarrange-link

dnarrange-link infers the order and orientation of read groups that are suspected to cover parts of a larger rearrangement. In other words, it infers how the groups are linked to each other, and thereby reconstructs the derived chromosomes. It uses (the alignments of) one representative read per group. The representative could be one actual read, or a consensus sequence (in this study, a lamassemble consensus sequence). Based on the
alignments, the two ends of each read are classified as "left" if the alignment extends rightwards/downstream along the chromosome starting from that end (shown as "[" in Additional file 1: Fig. S4) or "right" if the alignment extends leftwards/upstream ("]"). Two ends may be directly linked only if:

- They are on the same reference chromosome.
- One is left and the other is right.
- The left end is downstream of (has higher reference coordinate than) the right end. In order to infer the actual links, we require some further information or assumption. We make this assumption: there are as many links as possible, or equivalently, the derived genome has as few chromosomes as possible. For example, in Additional file 1: Fig. S4a, B1 may be linked to C 2 , but in that case it becomes impossible to link C 1 to anything, and D1 to anything. Based on our assumption, we instead link B1 to C1 and D1 to C2. In this example, dnarrange-link infers two derivative chromosomes: one is reconstructed from two reads by linking A2 to E1, the other is reconstructed from three reads by linking D1 to C2 and C1 to B1 (Additional file 1: Fig. S4b).

The two types of end, with linkability relationship, define a bipartite graph. To infer the links based on our assumption, we find a "maximum matching" in this graph. If there is more than one maximum matching, one is chosen arbitrarily, and a warning message is printed. In Additional file 1: Fig. S4, there is only one maximum matching

In Additional file 1: Fig. S4a, the left and right ends occur in an alternating pattern along each reference chromosome. In this case, we get a unique maximum matching by linking adjacent left and right ends. This alternating pattern seems to occur often in practice

## Coordinates of left and right ends

 dnarrange-link needs to decide whether a left end is "downstream of" a right end, i.e. whether it is rightwards/downstream in the chromosome. We wish to allow for some overlap,and some slop in the alignments. In the current version, dnarrange-link crudely defines the chromosome coordinate of a (left or right) end as: the average of the start and end coordinates of the alignment at that end.

## Alignment to human reference genome

Reads were aligned to human reference genome (hg38) using LAST version 959 (http://last.cbrc.jp) as follows. First, the genome was analyzed by WindowMasker [5] and a converted into a LAST database:

```
windowmasker -mk_counts -in hg38.fa > hg38.wmstat
windowmasker -ustat hg38.wmstat -outfmt fasta -in hg38.fa > hg38-wm.fa
lastdb -P8 -uNEAR -R11 -c hg38 hg38-wm.fa
```

This LAST database can be re-used for any future reads. Then, last-train was used to determine the rates of small insertions, deletions, and each kind of substitution between reads and genome:
last-train -P8 hg38 reads.fa > train.out
This training result can be re-used for any future reads that are expected to have the same rates (e.g. same sequencing hardware and base-calling software). Finally, the alignments were determined by:
lastal -P8 -p train.out hg38 reads.fa | last-split $-m 1>$ alns.maf
(Since LAST version 983, "-m1" can be omitted, because it is the default setting.)

## Finding reads with translocations and complex rearrangements

Rearrangements were found using dnarrange (https://github.com/mcfrith/dnarrange):

```
dnarrange -s3 patient.maf > patient-groups.maf
```

dnarrange finds rearranged reads, and groups those reads that share a rearrangement.
To remove rearrangements that are shared by other individuals, we used 33 controls (Figure 3, Additional file 1: Table S1):

```
dnarrange -s3 patient.maf : control.maf > patient-only.maf
```

Option -s3 means that the minimum number of supporting reads per group is 3 .
The patient-only groups file was re-analyzed with option -c1 to remove unreliable reads (Additional file 1: Fig. S3):

```
dnarrange -c1 -s3 patient-only.maf > final.maf
```


## Drawing dot-plot pictures of each group of rearranged reads

Dot plot pictures were obtained like this with some modification:

```
last-multiplot final.maf final-pic
```

Modified last-dotplot options were, for example:

```
last-dotplot -1 chr1:149390802-149390842 --sort2=3 --strands2=1 --rot1=v
```

--rot2=h --labels1=2 --rmsk1 rmsk.txt --genePred1 refFlat.txt
alignment.maf alignment.png
To draw gray lines joining breakpoints, this option was used: --join=2

## Assembly of reads and breakpoint detection

Each group of rearranged reads was merged into a consensus sequence like this: dnarrange-merge reads.fa train.out dnarrange-output $>$ consensus.fa Consensus sequences were re-aligned to the unmasked reference genome with these commands:

```
lastdb -P8 -uNEAR -R01 hg38 hg38.fa
```

last-train -P8 hg38 consensus.fa > train.out
lastal -P8 -p train. out hg38 consensus.fa| last-split -m1 > re-alns.maf

Breakpoints were determined from the re-aligned file:
dnarrange -s1 re-alns.maf > consensus-rearrangements
Then, dot-plot pictures were produced like this:
last-multiplot consensus-rearrangements dotplot-picture
lamassemble method
lamassemble merges overlapping DNA reads into a consensus sequence, by these steps:

1. Calculate the rates of insertion, deletion, and substitutions between two reads by "doubling" the rates from last-train, because errors occur in both reads.
2. Use these rates to find pairwise alignments between the reads with LAST. LAST also calculates the probability that each pair of bases is wrongly aligned (which is high when there are alternative alignments with near-equal likelihood).
3. Use the LAST alignments in descending order of score to define a tree for progressive alignment by MAFFT.
4. Constrain the MAFFT alignment by anchoring pairs of bases that were aligned by LAST with error probability $<=0.002$.
5. Make a consensus sequence from the MAFFT alignment. Omit alignment columns with gaps in $>50 \%$ of sequences covering that column. For each column, get the base that maximizes prob (base|column), using the last-train substitution probabilities.

Some results using a prototype of lamassemble were published previously [6].

## lamassemble details

## "Doubling" of substitution probabilities in lamassemble

From last-train, we have a $4 x 4$ matrix $P(x, y)$ : the probability of read base $y$ aligned to genome base $x$. These 16 probabilities sum to 1 . Let us define $c(x)$ to be the complement of base $x$, and $G(x)$ the probability of base $x$ in the genome: $G(x)=\operatorname{sum}(y$ in $a, c, g, t) P(x, y)$. For the subsequent steps to make sense, we require that $G$ has parity: $G(x)=G(c(x))$. lamassemble forces parity by rescaling:

$$
\begin{aligned}
& \mathrm{G}^{\prime}(\mathrm{x})=[\mathrm{G}(\mathrm{x})+\mathrm{G}(\mathrm{c}(\mathrm{x}))] / 2 \\
& \mathrm{P}^{\prime}(\mathrm{x}, \mathrm{y})=\mathrm{P}(\mathrm{x}, \mathrm{y})^{*} \mathrm{G}^{\prime}(\mathrm{x}) / \mathrm{G}(\mathrm{x})
\end{aligned}
$$

It then calculates the probability of base x in a read forward strand aligned to base y in a read forward strand:

$$
F(x, y)=\operatorname{sum}(z \text { in } a, c, g, t)\left[P^{\prime}(z, x)^{*} P^{\prime}(z, y) / G^{\prime}(z)\right]
$$

And the probability of $x$ in a read forward strand aligned to $y$ in a read reverse strand:

$$
R(x, y)=\operatorname{sum}(z \text { in } a, c, g, t)\left[P^{\prime}(z, x)^{*} P^{\prime}(c(z), c(y)) / G^{\prime}(z)\right]
$$

## "Doubling" of gap probabilities in lamassemble

last-train calculates read-to-genome gap probabilities like this[7]:
delOpenProb $=$ delOpenCount $/ n$
insOpenProb $=$ insOpenCount $/ n$
delExtendProb $=($ delCount - delOpenCount $) /$ delCount
insExtendProb $=($ insCount - insOpenCount $) /$ insCount
lamassemble crudely calculates these read-to-read gap probabilities:

```
gapOpenProb = 1- (1-delOpenProb) * (1 - insOpenProb)
gapExtendProb = (gapCount - gapOpenCount)/ gapCount
```

where:

$$
\begin{aligned}
& \text { gapCount = delCount + insCount } \\
& \text { gapOpenCount = delOpenCount + insOpenCount }
\end{aligned}
$$

By basic algebra, we can calculate gapExtendProb in terms of the four gap probabilities from last-train.

## Alignment in lamassemble

lamassemble finds pairwise alignments between the reads like this:

```
lastdb -uNEAR -c -RO1 -W19 my_db seq_file
lastal -j4 -Dle9 -m5 -z30g -s1 -p fwd_scores my_db seq_file
lastal -j4 -D1e9 -m5 -z30g -s0 -p rev_scores my_db seq_file
```

where the 1 st lastal command compares read forward strands to each other, and the 2nd lastal command compares forward strands to reverse strands. Alignments of a sequence to itself are discarded.

The alignments are sorted in descending order of score. For each alignment in turn:

* Record a link between the 2 aligned sequences, only if they are not yet linked directly or indirectly. This link defines the next step of progressive alignment. The (forward or reverse) strands in the alignment define which strands will be used for progressive alignment.
* If the alignment uses forward/reverse strands inconsistent with strands aligned (directly or indirectly) by previous alignments: discard this alignment.
* If the alignment is not "roughly colinear" with previous alignments of these 2 sequences: discard it. Two alignments $A$ and $B$, between sequences $S$ and $T$, are "roughly colinear" if: start_coordinate $(A, S)$ < start_coordinate $(B, S)$
start_coordinate $(A, T)$ < start_coordinate $(B, T)$
end_coordinate $(A, S)$ < end_coordinate $(B, S)$
end_coordinate $(A, T)$ < end_coordinate $(B, T)$

Before running MAFFT, lamassemble trims bases at the start and end of each sequence that are outside any non-discarded LAST alignment.

## Inferring retrotransposition

We inferred that many of the patient-specific rearrangements are retrotransposon integrations, by manual inspection and comparison to genome annotation from RepeatMasker (http://www.repeatmasker.org). It is not necessarily easy to distinguish retrotransposition from other types of rearrangements that happen to overlap retrotransposons. Our main criterion was whether the rearrangement involves a retrotransposon of a type known to be active or polymorphic (e.g. L1HS, AluYa5, AluYb8, SVA, ERVK). These elements are a tiny fraction of genomic repeats (e.g. $\sim 0.2 \%$ of L1 annotations are L1HS, $\sim 0.2 \%$ of Alus are AluYb8, $\sim 0.3 \%$ of Alus are AluYa5), but overlap a large fraction of our rearrangements. Moreover, some rearrangements are near-exact
insertions of whole retrotransposons (e.g. Additional file 1: Fig. S8, group 60, 61, 65, 72): this would be an extreme coincidence if it were not retrotransposition of such an element. Retrotransposition often exhibits 5'-truncation [8]: accordingly, we observe insertions that coincide with the 3 '-end of a retrotransposon (e.g. Additional file 1: Fig. S11, group 26). A thorough survey of retrotransposition could consider other hallmarks, such as target site duplication and LINE-1 endonuclease consensus sequence [8].

## Gene expression levels in lymphoblastoid cell

Total RNA was extracted from lymphoblastoid cells from Patient 3, and 3 controls, using RNeasy Plus Mini Kit (QIAGEN, Hilden, Germany), then subjected to reverse-transcription reaction using SuperScriptIII (Thermo Fisher Scientific). Quantitative real-time PCR was performed using Rotor-Gene SYBR Green PCR Kit and Rotor-Gene (QIAGEN, Hilden, Germany). Primers used were described in Additional file 1: Table S2. delta-delta CT method was used to compare gene expression levels of SEM1.

## Breakpoint detection by NanoSV and Sniffles

NanoSv website (https://github.com/mroosmalen/nanosv) states: "we found that LAST alignments give the most accurate results for SV calling with NanoSV". Thus we used the same alignment file we used for dnarrange. NanoSv -1.2.3 was installed via miniconda3, then run like this:

```
NanoSV -t 8 -s path-to-samtools -b hg38.bed -o out.vcf input.sorted.bam
``` NanoSV results using LAST alignment is named LAST-NanoSV hereafter. For Sniffles, ngmlr was used to align long reads to reference genome. Then SVs are found by Sniffles.
ngmlr -0.2.4 (https://github.com/philres/ngmlr) and sniffles -1.0.11 (https://github.com/fritzsedlazeck/Sniffles) were used like this:
```

ngmlr -t 16 -r hg38 -q input.fa -x ont -o out.sam
sniffles -m out.sorted.bam -v out.vcf -s 3

```

The results are named ngmlr-Sniffles hereafter.

\section*{Supplementary Results}

\section*{Gene expression level of possible causative genes in Patient 3}

Patient3 had a phenotype of split-hand/foot malformation (SHFM) with hearing loss, delayed development, self-injuries, hyperactivity and sleep disorders. SHFM has several causative loci, and one has been mapped to 7q21.3-q22.1[9]. Three genes SEM1, DLX5 and DLX6 are suggested to be related to SHFM with hearing impairment[10]. None of the three genes are disrupted in this patient (Additional file 1: Fig. S14a), which is also true of other SHFM patients, suggesting some regulatory effect of the rearrangement of flanking regions in SHFM[10]. To test the effect of the complex rearrangement on expression of those genes, we analyzed mRNA expression levels using the patient's lymphoblastoid cells (LCL). As we found out that SEM1 was expressed in LCLs, we analyzed expression level of SEM1. Expression levels of SEM1 cDNA were evaluated by quantitative polymerase chain reaction (qPCR) in the patient and three healthy controls. SEM1 expression of LCLs in this patient was not lower than the controls (Additional file 1: Fig. S14b). We could not test DLX5 and DLX6 because those genes were not expressed in LCLs. It is possible these two gene(s) are contributing to disease pathogenesis.

\section*{TE insertions, processed pseudogene insertions and nuclear mitochondrial} sequences

Large fractions of patient-specific rearrangements were smaller-scale rearrangements including tandem duplications or insertions. Among insertions, many of them were annotated as transposable elements, especially L1HS, AluYa5 or AluYb8 (Additional file 2: Table S12). Comparison of the fraction of patient-only TE-insertions (patients) to all TEs from RepeatMasker annotations (rmsk) from the UCSC genome browser (https://genome.ucsc.edu), suggests that these active TEs are enriched in patientonly insertions (Additional file 1: Fig. S21), supporting the notion that recently integrated TEs are the source of these genomic variations. In addition, we observed an ERVK insertion in Patient1 (Fig 4e), which was previously described[11]. We also identified an SVA insertion
shared by patients 2 and 3 (Additional file 2: Table S12: group1 in Patient 2 and group6 in Patient 3).

Aside from these TE insertions, there were insertions which were aligned to multiple exons of genes that are located distant from the insertion sites, possibly due to processed pseudogene insertion, in 3 patients (Figure 6g, Additional file 1: Fig. S11, S18). Insertions were from exons of MFF, MATR3 and FXR1 genes, in patient 2, 3 and 4, respectively. MFF and MATR3 processed pseudogene insertions into these loci were described previously[12], but not FXR1. This kind of rare structural variation might be commonly present in our genomes because we observed it in \(3 / 4\) patients in this study, although further study of multiple individuals may be necessary to conclude.

We also observed nuclear mitochondrial sequence (NUMT) in Patients 1 and 2 (Fig 4e, Additional file 1: Fig. S11, Table S11, Additional file 2: Table S12). Two of them are inserted into LINE regions of introns of SPAG16 and CEP128, respectively. In all NUMTs, there were flanking A-T oligomers at the insertion loci as suggested previously (Additional file 1: Table S11)[13].

Supplementary Tables
\begin{tabular}{|c|c|c|c|c|c|c|c|c|}
\hline & Sequencer & Ethnicity & Disease & Median length & Mean length & number of reads & total base & exprected coverage \\
\hline Patient1 & PromethION & Caucasian & Primary ovarian failure & 13,104 & 12,957.9 & 8,642,604 & 111,990,048,861 & 37 \\
\hline Patient2 & PromethION & Japanese & Primary ovarian failure & 3251 & 6,837.4 & 17,131,141 & 117,132,669,422 & 39 \\
\hline Patient3 & PromethION & Japanese & Bilateral split-foot malformation & 3223 & 6,333.2 & 14,926,358 & 94,531,709,149 & 32 \\
\hline Patient4 & PromethION & Japanese & West syndrome & 2334 & 6,004.3 & 6,845,364 & 41,101,961,286 & 14 \\
\hline Control1 & PromethION & Japanese & Epilepsy & 17,218 & 19,058.7 & 5,074,319 & 96,709,785,254 & 32 \\
\hline Control2 & PromethION & Japanese & Unaffected family control (father of control1) & 18,142 & 20,203.6 & 4,497,556 & 90,866,959,081 & 30 \\
\hline Control3 & PromethION & Japanese & Unaffected family control (mother of control1) & 16,986 & 18,521.5 & 4,403,236 & 81,554,440,718 & 27 \\
\hline Control4 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 1,558 & 4,477.8 & 12,830,261 & 57,451,863,375 & 19 \\
\hline Control5 & PromethION & Japanese & Unaffected family control & 2,452 & 3,632.9 & 9,635,261 & 35,004,315,947 & 12 \\
\hline Control6 & PromethION & Japanese & Unaffected family control & 691 & 2,340.2 & 23,303,818 & 54,535,886,940 & 18 \\
\hline Control7 & PromethION & Japanese & Renal hypoplasia & 7,127 & 9,953.0 & 7,824,636 & 77,878,925,289 & 26 \\
\hline Control8 & PromethION & Japanese & WEST syndrome & 14,670 & 15,094.4 & 3,557,359 & 53,696,135,713 & 18 \\
\hline Control9 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 3,520 & 5,203.2 & 15,926,839 & 82,870,233,437 & 28 \\
\hline Control10 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 3,298 & 5,466.3 & 10,589,493 & 57,885,853,963 & 19 \\
\hline Control11 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 2,990 & 5,598.3 & 11,109,622 & 62,195,375,599 & 21 \\
\hline Control12 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 3,736 & 6,820.9 & 10,658,181 & 72,698,332,750 & 24 \\
\hline Control13 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 3,169 & 7,012.2 & 5,529,417 & 38,773,128,508 & 13 \\
\hline Control14 & PromethION & Japanese & Unaffected family control & 5,889 & 7,025.5 & 9,091,759 & 63,874,106,363 & 21 \\
\hline Control15 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 1,608 & 2,773.6 & 17,969,232 & 49,838,565,927 & 17 \\
\hline Control16 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 3,520 & 8,162.9 & 6,786,707 & 55,398,873,781 & 18 \\
\hline Control17 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 3,110 & 4,902.2 & 11,467,114 & 56,214,013,607 & 19 \\
\hline Control18 & PromethION & Japanese & Neuronal Intranuclear Inclusion disease & 3,861 & 5,785.1 & 13,655,084 & 78,995,795,042 & 26 \\
\hline Control19 & PromethION & Japanese & Focal cortical dysplagia & 3,425 & 5,036.7 & 17,761,209 & 89,558,068,739 & 30 \\
\hline Control20 & PromethION & Japanese & Epilepsy & 3,392 & 6,540.9 & 10,500,704 & 68,684,084,437 & 23 \\
\hline Control21 & PromethION & Japanese & Epilepsy & 3,382 & 6,645.8 & 9,582,128 & 63,680,708,046 & 21 \\
\hline Control22 & PromethION & Japanese & Epilepsy & 2,645 & 5,105.2 & 12,998,831 & 66,361,384,504 & 22 \\
\hline Control23 & PromethION & Japanese & Epilepsy & 2,035 & 4,135.6 & 20,502,426 & 84,790,477,596 & 28 \\
\hline Control24 & PromethION & Japanese & Brain abnormality & 3,893 & 7,265.3 & 17,229,947 & 125,180,249,687 & 42 \\
\hline Control25 & PromethION & Japanese & Cerebellar ataxia & 3,601 & 6,305.7 & 17,880,435 & 112,748,995,082 & 38 \\
\hline Control26 & PromethION & Japanese & Epilepsy & 2,744 & 6,002.9 & 16,280,893 & 97,732,025,016 & 33 \\
\hline Control27 & PromethION & Japanese & Epilepsy & 1,719 & 3,774.3 & 23,432,032 & 88,440,096,328 & 29 \\
\hline Control28 & PromethION & Japanese & Epilepsy & 20,468 & 22,153.9 & 2,313,819 & 51,571,485,654 & 17 \\
\hline Control29 & PromethION & Japanese & Benign adult familiay myoclonic epilepsy & 3,087 & 4,884.0 & 8,709,727 & 42,536,118,154 & 14 \\
\hline Control30 & PromethION & Japanese & Benign adult familiay myoclonic epilepsy & 2,126 & 3,295.0 & 13,143,397 & 43,307,793,923 & 14 \\
\hline Control31 & PromethION & Japanese & Benign adult familiay myoclonic epilepsy & 13,749 & 15,332.0 & 2,515,618 & 38,569,602,139 & 13 \\
\hline Control32 & PromethION & Japanese & Benign adult familiay myoclonic epilepsy & 12,248 & 13,319.0 & 3,795,124 & 50,547,125,919 & 17 \\
\hline Control33 & PromethION & Caucasian & Ablepharon and macrostomia & 9,606 & 9,072.5 & 10,503,537 & 95,293,663,017 & 32 \\
\hline
\end{tabular}

Table S1. Summary of PromethION sequencing data.
\begin{tabular}{|c|c|c|c|c|c|}
\hline & & group & Forward & Reverse & \\
\hline Patient & \multicolumn{5}{|l|}{breakpoint PCR} \\
\hline \multirow[t]{2}{*}{Patient 1} & der-chr2 & 3 & gggcaacaatttccacattgaa & tccectgtgatggacttaacaag & Fig S7b \\
\hline & der-chrX & 9 & gtttggaagtcttggttcccag & gcattagtctttgcacctgtgag & Fig S7b \\
\hline \multirow[t]{7}{*}{Patient 2} & der-chr4 & 2 & tccetagagaatccccaagtc & ttgcctactettactcttcagcc & Fig S10b, c \\
\hline & der-chrX & 5 & tgcctttcatgataagctctgg & gaatgttttgaggccttgc & Fig S10b,c \\
\hline & chrX del & 10 & ccacaattggtgagtgtccttac & tgagactcaattccaattgtaggc & Fig S10b,c \\
\hline & complex chri1-1 & 6 & cttattccetctcatagatgcac & ggaaacatcttcagacagaaactag & Fig S12a,b \\
\hline & complex chr11-2 & 6 & ccaattcagtgaggaaagtcattg & gaacattgggagttattgaggtc & Fig S12a,b \\
\hline & complex chr11-3 & 12 & ctaaaattcagcagcgttatcaaat & gaaaggacaaaaagagttatgcaa & Fig S12a,b \\
\hline & complex chr11-4 & 16 & tgtgctgtcttactggtaagtgta & ccgatgacaattagacattcttggg & Fig S12a,b \\
\hline \multirow[t]{19}{*}{Patient 3} & der-chr7 & 18 & caggaaataagagactggttcctaa & catgttactgcagatgatgagatt & Fig S15a \\
\hline & der-chr15 & 17 & tgattagctctgtacctgaggactt & aaaggattacattgtgatgcaaact & Fig S15b \\
\hline & & 13 & ttccagagcgattgtattattagc & tcaatggcagtactagattcacaac & Fig S15c \\
\hline & & 1 & gttaatttaagcgtcccacctaat & tgaaacaagccgtatgtatgatatg & Fig S15d-1 \\
\hline & & 1 & aactctctcatcacatggttcatt & actaacaagcagggatacaaacaag & Fig S15d-2 \\
\hline & & 5 & agaattggaaaagagatcttgtgtg & aaccotgtaaatgtggaattctgta & Fig S15e-1 \\
\hline & & 5 & agtgaattccattcagtgtaccatt & gatatagcaggcatcctatttgtg & Fig S15e-2 \\
\hline & & 5 & ccatagatggatacatggataaaca & actcagacttgtaggtaaccccatt & Fig S15e-3 \\
\hline & & 12 & tatagcttgaaggaattccattgt & gctatccagagcatggtctattcta & Fig S15f \\
\hline & & 35 & atagtagctgcttgtgcctgtaatc & ggtgatggttatggttatcttctca & Fig S15g \\
\hline & & 3 & accagagaattgaagatgactatgg & aattgtgggaggtaattatccattt & Fig S15h \\
\hline & der-chr9 & 21 & agctagacctgcaatagcaaactta & gcattagaaaccattcctgtagaa & Fig S15i \\
\hline & & 33 & atttgtgaactctgacttgaggaag & ataacttcttataatgtattaaccatgctgtag & Fig S15j \\
\hline & & 11 & ctgcatggaagtaggggtgt & acactggcccacaaaaagag & Fig S15k \\
\hline & & 30 & ccagtctaggacctctcttagtactttat & cccaactctctaatgttctactacttact & Fig S15I \\
\hline & & 22 & ggttcttatatattctggttattaattcttgt & ctagtccttcccaacacattagtttat & Fig S15m \\
\hline & & 21 & ggaaggcaaattcaatccaa & acctggctcacaaggtatgg & Fig S15n \\
\hline & der-chr14 & 6 & cctgacctagaactgtcccactaag & accaagatgttctacaaaaagcac & Fig S150 \\
\hline & \multicolumn{5}{|l|}{AluYb5 PCR} \\
\hline \multirow[t]{3}{*}{Patient 1} & & 51 & ctgtgaacaacctagtctttgg & gctgccotcagaagaataaatg & Fig S9 \\
\hline & & 65 & tccttaataccaacactgcacctc & cttcaaattgttcctcaggggattc & Fig S9 \\
\hline & & 72 & ttcaggtctctcagcccagcatc & ggatccetttccagtaacagcacc & Fig S9 \\
\hline \multicolumn{6}{|c|}{QPCR} \\
\hline Patient 3 & SEM1 & & cagttacgagctgaactagagaaa & gggttcttgaccctagaatgt & \\
\hline
\end{tabular}

Table S2. Primers.
Primers used to confirm breakpoints and qPCR in Patient1, 2 and 3.
\begin{tabular}{|c|c|c|c|c|}
\hline & Patient1 & Patient2 & Patient3 & Patient 4 \\
\hline Original & 2,773 & 3,336 & 3,351 & 2,523 \\
\hline data1 & 1,392 & 2,858 & 2,075 & 1,302 \\
\hline data2 & 794 & 1,860 & 1,206 & 806 \\
\hline data3 & 539 & 1,257 & 804 & 570 \\
\hline data4 & 409 & 609 & 428 & 292 \\
\hline data5 & 367 & 459 & 316 & 225 \\
\hline data6 & 307 & 335 & 234 & 140 \\
\hline data7 & 267 & 262 & 186 & 106 \\
\hline data8 & 246 & 228 & 160 & 98 \\
\hline data9 & 218 & 182 & 136 & 79 \\
\hline data10 & 204 & 159 & 120 & 66 \\
\hline data11 & 194 & 147 & 112 & 58 \\
\hline data12 & 181 & 122 & 103 & 51 \\
\hline data13 & 171 & 111 & 96 & 47 \\
\hline data14 & 164 & 105 & 92 & 45 \\
\hline data15 & 162 & 99 & 87 & 39 \\
\hline data16 & 160 & 93 & 82 & 36 \\
\hline data17 & 156 & 89 & 79 & 36 \\
\hline data18 & 151 & 82 & 77 & 35 \\
\hline data19 & 144 & 74 & 70 & 32 \\
\hline data20 & 141 & 71 & 67 & 32 \\
\hline data21 & 141 & 68 & 66 & 30 \\
\hline data22 & 137 & 66 & 63 & 29 \\
\hline data23 & 133 & 61 & 62 & 29 \\
\hline data24 & 129 & 54 & 59 & 29 \\
\hline data25 & 125 & 52 & 54 & 28 \\
\hline data26 & 124 & 48 & 51 & 27 \\
\hline data27 & 122 & 48 & 50 & 24 \\
\hline data28 & 121 & 46 & 48 & 22 \\
\hline data29 & 119 & 46 & 47 & 22 \\
\hline data30 & 119 & 45 & 47 & 21 \\
\hline data31 & 118 & 42 & 47 & 21 \\
\hline data32 & 117 & 41 & 47 & 21 \\
\hline data33 & 101 & 37 & 46 & 21 \\
\hline with -c1 option & 80 & 33 & 43 & 14 \\
\hline
\end{tabular}

Table S3. Number of groups of rearranged reads in each patient, after successive filtering using 33 control humans. Original: number of groups in each patient before filtering.
\begin{tabular}{ccccccc}
\hline & & & & & & \\
& Patient1 & Patient2 & Patient3 & Patient4 & sniffles & NanoSV \\
\hline real & 205 m 48.036 s & 234 m 9.006 s & 154 m 17.363 s & 134 m 53.602 s & 198 m 40.757 s & 5361 m 3.771 s \\
user & 202 m 43.690 s & 232 m 40.968 s & 153 m 2.223 s & 133 m 49.292 s & 420 m 38.719 s & 3446 m 56.912 s \\
sys & 2 m 51.771 s & 1 m 30.713 s & 1 m 19.762 s & 1 m 5.775 s & 2 m 6.462 s & 2627 m 25.827 s \\
& & & & & \\
\hline
\end{tabular}

Table S4. Computational time usage for grouping rearranged reads from the patient and subsequent filtering using 33 controls, and other SV detection tools. real: wall clock time. user: CPU time. sys: CPU time within the system.
\begin{tabular}{rrrrr}
\hline & \multicolumn{6}{l}{ alignment to GRCh38 } & & & minimap2 \\
\cline { 2 - 6 } & NGMLR & last-train (v1060) & LAST (v1060) -P16 & \\
\hline real & 2739 m 1.616 s & & & \\
user & 43091 m 36.694 s 24.576 s & 1234 m 29.371 s & 693 m 22.452 s \\
sys & 397 m 45.575 s & 43 m 39.373 s & 10368 m 58.192 s & 2102 m 22.897 s \\
Max resident set size(kbytes) & \(76,358,704\) & 1 m 4.917 s & 10 m 7.432 s & 10 m 56.283 s \\
& & \(11,662,304\) & \(12,015,872\) & \(47,371,760\) \\
\hline
\end{tabular}

Table S5. Computational time usage of LAST and other aligners. real: wall clock time. user: CPU time. sys: CPU time within the system.
\begin{tabular}{lcccc}
\hline & Patient1 & Patient2 & Patient3 & Patient4 \\
\hline & 15 & & & \\
tandem multiplication & 13 & 6 & 7 & 3 \\
tandem repeat expansion & 16 & 6 & 3 & 1 \\
retrotransposition & 9 & 4 & 3 & 1 \\
non-tandem duplication (insertion) & 3 & 0 & 0 & 0 \\
non-tandem duplication with target site deletion & 1 & 3 & 1 & 0 \\
large tandem duplication & 8 & 1 & 5 & 2 \\
deletion & 1 & 0 & 1 & 1 \\
inversion & 0 & 1 & 1 & 1 \\
processed pseudogene insertion & 1 & 2 & 0 & 0 \\
NUMT & 7 & 2 & 4 & 2 \\
unclear & 2 & 2 & 0 & 0 \\
chromosomal translocation & 2 & 0 & 0 & 0 \\
possible inversion duplication & 0 & 3 & 15 & 0 \\
complex rearrangement & & & & \\
\hline
\end{tabular}

Table S6. Number of patient-only rearrangements in each category. NUMT: nuclear mitochondrial DNA insertions.
\begin{tabular}{|c|c|c|}
\hline chr & Fig. S12 & Sequnce in between breakpoints \\
\hline \multirow[t]{11}{*}{\[
\begin{array}{r}
\operatorname{der}(7) \\
\operatorname{der}(15)
\end{array}
\]} & a & G overlap \\
\hline & b & AT microhomology \\
\hline & c & AG microhomology \\
\hline & d-1 & blunt \\
\hline & d-2 & T insertion \\
\hline & e-1 & C overlap \\
\hline & e-2 & A insertion \\
\hline & e-3 & TTA microhomology \\
\hline & \(f\) & blunt \\
\hline & g & TC microhomology \\
\hline & h & blunt \\
\hline \multirow[t]{5}{*}{der(9)} & i & blunt \\
\hline & j & blunt \\
\hline & k & ACTTCAGG insertion \\
\hline & I & blunt \\
\hline & m & blunt \\
\hline der(4) & n & blunt \\
\hline der(14) & o & T overlap \\
\hline
\end{tabular}

Table S7. Sequence features of 18 breakpoints in Patient 3.
Most of the breakpoints show blunt end or microhomology-mediated ligation.
\begin{tabular}{|c|c|c|c|c|c|c|}
\hline \multirow[b]{2}{*}{Examples} & \multirow[b]{2}{*}{types of rearrangement} & \multicolumn{5}{|l|}{NanoSV calls} \\
\hline & & chr & position & ref & alt & SV length \\
\hline \multirow[t]{5}{*}{Patient 1 (Fig. 4e)} & AluYa5 insertion & chr1 & 3211404 & T & <INS> & 287 \\
\hline & AluYb8 insertion & chr12 & 58987676 & A & <INS> & 288 \\
\hline & & chr12 & 58987679 & A & ]chr2:18580627]A & \\
\hline & L1HS insertion & chr2 & 198915190 & T & T[chr4:149915528[ & \\
\hline & ERVK insertion & chr12 & 123581929 & A & ]chr15:58834291]A & \\
\hline \multirow[t]{9}{*}{Patient 3 (Fig. 6g)} & Processed pseudogene/AluYa5 insertion & chr15 & 93296473 & T & [chr2:227325268[T & \\
\hline & & chr15 & 93296485 & T & T]chr2:227357830] & \\
\hline & & chr15 & 93292543 & A & <INS> & 235 \\
\hline & & chr2 & 227210436 & A & A[chr2:227210535[ & \\
\hline & & chr2 & 227325428 & G & G[chr2:227328680[ & \\
\hline & & chr2 & 227328788 & T & T[chr2:227329606[ & \\
\hline & & chr2 & 227329782 & A & A[chr2:227330626[ & \\
\hline & & chr2 & 227352569 & G & <DEL> & 3105 \\
\hline & & chr2 & 227355757 & G & <DEL> & 1227 \\
\hline
\end{tabular}

Table S8. Examples of NanoSV calls for the TE-insertions of Patient 1 and processed pseudogene-AluYa5 insertion in Patient 3. AluYa5 insertion in Patient 3 was not detected.
\begin{tabular}{lll}
\hline \# in Fig. S19 & type & Inheritance \\
\hline & TE-insertion (SINE-MIR) & paternal \\
group1 & inversion & maternal \\
group2 & (TA)n insertion & paternal \\
group3 & tandem duplication & paternal \\
group4 & TE insertion (SVA_F) & maternal \\
group5 & inversion and deletion & paternal \\
group6 & deletion & paternal \\
group7 & deletion & maternal \\
group8 & deletion & maternal \\
group9 & TE insertion (L1HS 3'end) & maternal \\
group10 & TE insertion (SVA_E) & maternal \\
group11 & tandem duplication & maternal \\
group12 & tandem duplication & paternal \\
group13 & tandem duplication & maternal \\
group14 & tandem duplication & paternal \\
group15 & deletion & paternal \\
group16 & tandem duplication? & maternal \\
group17 & deletion & paternal \\
group18 & TE insertion (L1HS 5'end) & paternal \\
group19 & tandem multiplication & maternal \\
group20 & TE insertion (SVA_D) & paternal \\
group21 & tandem duplication & maternal \\
group22 & TE insertion (SVA_E) & maternal \\
group23 & TE insertion (L1HS) & maternal \\
group24 & TE insertion (L1HS) & maternal \\
group25 & tandem multiplication? & paternal \\
group26 & TE insertion (L1HS_3'end) & maternal \\
group27 & & \\
\hline & & \\
\hline
\end{tabular}

Table S9. Trio analysis shows filtered rearrangements in child are inherited from either of the parents.


Table S10. Comparison to reported SVs in NA12878.
We checked large deletions (more than 5 kb ) in one human genome (NA12878) that were reported previously. To detect deletions \(>5 \mathrm{~kb}\), we added -g5000 option to dnarrange. Our pipeline without control filtering found rearrangements at the sites of all 30 reported deletions, but with further complexity in some cases.
\begin{tabular}{llllllllll}
\hline Patient & insert locus & insert length & strand & mt gene & mismap probability & insertion locus & insertion locus gene & RepeatMasker annotation & Near-by A-T sequence (<20bp) \\
\hline & & & & & & & & & \\
Patient1 & chrM:15065-151 & 36 & + & CYB & mismap=1.39e-05 & chr2:213419058-213419060 & SPAG16 intron & LINE L1 \\
Patient2 & chrM:10556-106 & 126 & - & ND4L & mismap=1e-10 & chr14:80547592-80547596 & CEP128 intron & LINE L2 & AATAAAA \\
Patient2 & chrM:11680-117 & 64 & + & ND4 & mismap \(=0.5\) & chr4:7252649-7252650 & SORCS2 intron & DNA/hAT-Blackjack & AAAAAT \\
\hline
\end{tabular}

\section*{Table S11 NUMT origin and insertion site.}

Nuclear Mitochondrial sequences (NUMT) found in Patient 1 and Patient2.

Table S12 is shown in a separate file (Additional file 2).

Table S12. Detailed description of patient-only rearrangements in Fig. S3, S6, S11 and S14.

Group25 in Patient1 is an L1HS insertion, which has a 3'-transduction indicating that the source is a specific L1HS in chr4. This chr4 L1HS is absent in the reference genome, but is present in some humans (hg18.chr4:129184647) [14]. For group 24 \& 52, inverted duplication in chr16 and chr20, are also present in public nanopore data NA12878 (rel3 and rel4. Jain et al.2018, detected by our analysis) [15], suggesting that a reported duplication (array CGH) or inversion (WGS) near this locus (International HapMap, C. et al. 2010, Genomes Project, C. et al. 2010) [16] [17] in NA12878, is actually identical to this inverted duplication. For group6, 12 and 16 in Patient2, dnarrange-link infers a chr11 complex rearrangement (Figure 5e).

Table S13 is shown in a separate file (Additional file 3).

Table S13. Comparison of the breakpoints detected by dnarrange, ngmlr-Sniffles and LAST-NanoSV to Sanger sequence-confirmed breakpoints.
Breakpoints were described according to vcf (variant call format) version 4.2 (https://cseweb.ucsd.edu/classes/sp16/cse182-a/notes/VCFv4.2.pdf). Note that in ngmlrSniffles and LAST-NanoSV, we only look for translocation sites (suggested by G-banded chromosomal analysis) because there is no method to filter out common/benign changes present in controls.
a Inter-chromosome

\section*{Chromosome A Chromosome B}

b inter-strand


\section*{C Non-colinear}

Chromosome A


\section*{Chromosome A}


Fig 51.
The four types of rearrangement. Note this is not a classification of whole rearrangement phenomena (e.g. gene conversion, processed pseudogene insertion). This is a classification of minimal rearrangements, which could be parts of larger wholes.


Fig S2. Sketch of the information considered by dnarrange to judge whether two reads share a rearrangement.
Note that \(\mathrm{m}, \mathrm{n}, \mathrm{r}\), and s are not absolute values: they may be less than zero. For example, n equals the chromosomal start coordinate of \(Y\) minus the chromosomal start coordinate of \(B\). In the example shown here: \(\mathrm{m}, \mathrm{n}, \mathrm{r}\), and s are all greater than zero.


Fig S3. Example of rearrangements filtered by -c1 option.
a. Examples of rearranged reads, where we suspect the rearrangements to be artifacts of the sequencing process, which were excluded by running dnarrange with option -c1 (they are likely to be artifacts because almost the same length of reverse complimentary strand starts from the end of the other strand: we suspect this might be caused by the chimeric reads generated from the other strand of the nanopore DNA library). Three groups of rearranged reads are shown.
b. In this group of rearranged reads, two reads with unique rearrangements were excluded by the -c1 option.
a

b

\section*{derivative chr \(R\)}


\section*{derivative chr S}

Fig S4. Illustration of data analyzed by dnarrange-link
a. The sketch shows alignment of five DNA reads (A, B, C, D, E) to a genome. The two ends of each read are arbitrarily labeled 1 and 2. b. Derivative chr \(R\) was reconstructed by linking A2 to E1 (left). Derivative chr \(S\) was reconstructed by linking B1 to C1, and D1 to C 2 (right). B1 can also be linked to C 2 , but in that case it is impossible to link C 1 to anything, and D1 to anything, thus this possibility was suppressed.


Fig S5. Effect on rearrangement numbers and filtering of changing -g and -r option.
Using -g100 and -r1 options which counts small deletions and duplications detects more rearrangements at first. By filtering with 33 controls and -c1 option (x-axis), the number of rearrangements decrease exponentially and close to the default (-g10000, -r1000). a. Patient1, b. Patient2, c. Patient3, d. Patient4.
b
Patient 1
C Patient 1
group4
d Patient 3 group6
e Patient 3 group4
tandem
duplication
chr9:115,801,133
\(-115,847,234\)

inversion

\section*{chr13:37,297,849}


\section*{deletion or translocation}


Transposable element insertion (SVA)
large tandem duplication

\section*{chr8:94,190,000 chr20:2,822,000} \(-94,199,000 \quad-2,829,000\)



\section*{lamassemble}


Fig S6. Examples of grouped rearranged reads and consensus sequences.
Dot-plot of examples of grouped rearranged reads. In a dot-plot, a diagonal line is drawn where a read sequence (vertical) aligned to the reference sequence (horizontal). The horizontal black lines are boundaries between different dot-plots showing different DNA reads. a. tandem-multiplication. b. inversion. c. deletion or translocation. d. non-tandem duplication or translocation (insertion). In this dotplot, the inserted sequence is aligned to a transposable element (pale pink) e. possible large tandem duplication. It is not clear if this is a tandem duplication because no one read encompasses the whole duplication. However, this is the simplest interpretation unless other rearrangements are found in the region, thus we categorized this as large duplication. Examples a-c: Patient 1, d,e. Patient 3. The vertical stripes indicate annotations in the reference genome: tandem repeats (purple), transposable elements (pink:forward-strand, blue:reverse-strand), green (exon) and dark green (protein-coding sequence). Each group of reads was assembled by lamassemble: the resulting consensus sequences were realigned to the reference genome.
chr2:65,976,415 chrX:108,676,529
-66,000,996 -108,704,621

lamassemble
\(-66,000,827 \quad-108,704,449\)

b der-chr2
group9


der-chrX
 chrX CAGCCTCGTCA der-chrX CAGCCTCGTCATGCGGTCTT chr2

ATGCGGTCTT
chr2:65999178

Fig S7. Reciprocal chromosomal translocation in Patient 1.
(a) Dot-plot pictures of grouped rearranged reads and lamassemble consensus sequences at the translocation sites in Patient 1. Translocation \(\mathrm{t}(\mathrm{X} ; 2)(\mathrm{q} 22 ; \mathrm{p} 13)\) in Patient 1 does not lose any regions nor disrupt any genes. The vertical stripes indicate annotations in the reference genome: tandem repeats (purple), transposable elements (pink:forward-strand, blue:reverse-strand), green (exon) and dark green (protein-coding sequence). The horizontal black lines indicate boundaries between different dot-plots showing different reads. (b) Sanger sequence confirmation of the breakpoints.
tandem multiplication

tandem repeat expansion

group53


Large tandem duplications
group13



NUMT
group47


group63 group64

group66



AluYa5 insertion with tandem duplication

\section*{group49}


ERVK insertion
group70

group78


Non-tandem duplication or translocation (insertion)


\section*{Deletions}

non-tandem duplication with target-site deletion

\section*{group10}

group32


Inversions
group74



\section*{Unclear}


Fig S8. Other patient-only rearrangements in Patient 1.
Dot-plot pictures of lamassemble consensus sequences are shown. For some of the retrotranspositions (e.g. group57), the insertion is aligned to multiple chromosomes. In these cases, the insertion is aligned to different copies of the same type of retrotransposon (e.g. SVA). Our interpretation is that the true source copy is absent from (or misassembled in) the reference genome, so we get a fragmented alignment to different copies.


Fig S9. AluYa5 insertions in Patient 1
PCR confirmation for three TE-insertions in Patient1 (group51, 65 and 72). Primers were designed to amplify both normal and TE-inserted alleles. Agarose gel electrophoresis of the PCR products shows two PCR products in Patient 1 but not controls.
The expected band size estimated from dnarrange are shown (arrow heads).
Control: control individuals without a disease. NC: non DNA template control.
a

Patient 2 46,X,t(X;4)(q21.3;p15.2)
chr4:12,203,846 chrX:108,161,278 \(-12,237,984 \quad-108,195,327\)
group2

lamassemble

chr4:12,238,970 chrX:108,193,484
\(-12,284,239-108,255,145\)
group5

chr4:12,213,510 chrX:108,172,765

chr4:12,239,035 chrX:108,193,541

b

\section*{der-chr4}

chrX:108197172 chrXAAGACCCTA der-chr4 AAGACCCTAGAGATGTTGCCTC chr4
der-chrX

chrX:107,929,975 -108,006,361


\section*{deletion}


C

\section*{der-chr4}



\section*{der-chrX}

chrX deletion


Fig S10. Reciprocal chromosomal translocation in Patient 2.
Dot-plot pictures of grouped rearranged reads and lamassemble consensus sequences at the translocation sites in Patient 2. Translocation \(t(X ; 4)(q 21.3 ; p 15.2)\) in Patient 2 disrupts the COL4A6 gene. Near the translocation site, there is a 43-kb deletion, which eliminates the whole TEX13B gene. The vertical stripes indicate annotations in the reference genome: tandem repeats (purple), transposable elements (pink:forward-strand, blue:reverse-strand), green (exon) and dark green (protein-coding sequence). The horizontal black lines indicate boundaries between different dot-plots showing different reads. (b) Sanger sequence confirmation of the breakpoints. (c) Breakpoint PCR of the proband and parents shows the \(t(X ; 4)\) translocation is de novo but 43-kb deletion is inherited from father. Control: control individual without a disease. NC: non DNA template control.


AluYa5 insertion + tandem duplication group14


Non-tandem duplication or translocation (insertion)


Retrotransposition


Large tandem duplications
group7

group13


\section*{group30}


\section*{Processed-pseudogene insertion}


\section*{NUMT}
group9


\section*{group15}


\section*{Complex rearrangement}

\section*{group6}

group12


\section*{group16}


\section*{Unclear}

\section*{group22} group32

\begin{tabular}{|l|}
\hline \\
\hline \\
transposable elements \\
(reverse-strand) \\
transposable elements \\
(forward-strand) \\
\(\quad\) tandem repeat \\
\(\quad\) protein-coding sequence \\
\hline \\
exons \\
\hline
\end{tabular}

Fig S11. Other patient-only rearrangements in Patient 2.
Other patient-only rearrangements in Patient 2. Dot-plot pictures of lamassemble consensus sequence are shown. Patient 2 also has a processed-pseudogene insertion into chr12, which aligns to exons of MATR3 in chr5. Part of this insertion is aligned, perhaps incorrectly, to a MATR3 processed pseudogene in chr1.
a



2


3


4


Fig S12. complex chr11 rearrangement in Patient 2
a. PCR confirmation for complex chr11 rearrangement in Patient2. Four breakpoints are confirmed by PCR. This rearrangement was inherited from mother. Arrow heads: predicted PCR product size (bp). b. Sanger sequence confirmation of the breakpoints.


Fig S13. Rearrangement groups detected in two reciprocal chromosomal translocations in Patient 3.
Dot-plot pictures of lamassemble consensus sequences aligned to the human reference genome that explain translocation \(t(7 ; 15)(q 21 ; q 15)\) and \(t(9,14)(q 21 ; q 11.2)\) in Patient 3 . The vertical stripes indicate annotations in the reference genome: tandem repeats (purple), transposable elements (pink:forward-strand, blue:reverse-strand), green (exon) and dark green (protein-coding sequence).


Fig S14. Genes at the rearrangement loci in Patient 3. a. Joined rearranged fragments from Patient 3 are aligned to the reference genome and shown by UCSC genome browser. Several genes are completely deleted or disrupted by breakpoints. b. RT-PCR of SEM1. Error bars represent standard deviation.



Fig S15. Sanger-sequence confirmation of the breakpoints.
Sanger sequence confirmation of all 18 breakpoints in Patient 3. Electropherograms of the Sanger sequencing data of each breakpoint are shown with the schematic picture of the rearrangements.


Fig S16. Accuracy of breakpoint prediction by dnarrange confirmed by Sanger sequencing. Difference between Sanger sequence-confirmed breakpoints and dnarrange predictions. There is usually 0 or 1 bp difference from the Sanger-sequence results.

Tandem multiplication
group12



group30
group32



Tandem repeat expansion
group25 group29 group33


Large tandem duplications
group4


Inversion group34


Deletions (or translocations)


Retrotransposition

AluYb8 insertion \(\nabla\) group43


L1HS insertion group40


SVA insertion group6


\section*{group39}


Processed-pseudogene insertion
nearby AluYa5 insertion \(\nabla\)
group22


Unclear

transposable elements (reverse-strand)
transposable elements (forward-strand)
tandem repeat
protein-coding sequence exons

Fig S17. Other patient-only rearrangements in Patient 3.
Other patient-only rearrangements in Patient 3. Dot-plot pictures of lamassemble consensus sequences are shown. The vertical stripes indicate annotations in the reference genome: tandem repeats (purple), transposable elements (pink:forward-strand, blue:reverse-strand), green (exon) and dark green (protein-coding sequence).


Fig S18. Patient-only rearrangements in Patient 4.
Other patient-only rearrangements in Patient 4. Patient 4 has a processed pseudogene insertion from exons of FXR1. Part of this insertion is aligned, perhaps incorrectly, to an FXR1 processed pseudogene in chr12.


Fig S19. Control-1 only rearrangements.
We could identify 27 Control-1-only rearragements by using other unrelated 30 controls (Control-4 to Control-33). dnarrange automatically removed 14 of them using mother (Control-3), and 12 using father (Control-2) as controls. Group-23 was not filtered but this TE-insertion is present in Control-3.


19



23


27


\section*{}


24


21




25

28



29


30
\begin{tabular}{|l|l|}
\hline & transposable elements (reverse-strand) \\
\hline & transposable elements (forward-strand) \\
\hline & tandem repeat \\
\hline & protein-coding sequence \\
\hline & exons \\
\hline & bridged gap \\
& unbridged gap \\
& reported deletion
\end{tabular}

Fig S20. Published deletions in NA12878 were all detected by dnarrnage with further complexity. dnarrange from NA12878 nanopore sequencing (rel6, https://github.com/nanopore-wgs-consortium) identifies 30 published deletions. Eight of them have further complexity than simple deletions (3, 8, 9, 16, 18, 20, 28, 29).
For \(8,16,18,29\), we used latest lamassemble version (1.3.0) because it can handle repeats better. In site 30 , we find the deletion at a location shifted from what was reported. This region has tandem repeats, as indicated by the repeating pattern of vertical stripes. The deletion is of one repeat unit, so its location has some ambiguity. In site 28 , the reported deletion is also of one tandem repeat unit.


Fig S21. Active TEs are enriched in insertions.
Proportions of various transposable element types in the reference genome (rmsk, https://genome.ucsc.edu) and in patient-specific insertions (patients).

\section*{References}
1. Bano G, Mansour S, Nussey S: The association of primary hyperparathyroidism and primary ovarian failure: a de novo \(\mathrm{t}(\mathrm{X} ; 2)\) (q22p13) reciprocal translocation. Eur \(J\) Endocrinol 2008, 158:261-263.
2. Nishimura-Tadaki A, Wada T, Bano G, Gough K, Warner J, Kosho T, Ando N, Hamanoue H, Sakakibara H, Nishimura G, et al: Breakpoint determination of X;autosome balanced translocations in four patients with premature ovarian failure. J Hum Genet 2011, 56:156-160.
3. Saitsu H, Kurosawa K, Kawara H, Eguchi M, Mizuguchi T, Harada N, Kaname T, Kano H, Miyake N , Toda T, Matsumoto N : Characterization of the complex 7q21.3 rearrangement in a patient with bilateral split-foot malformation and hearing loss. Am J Med Genet A 2009, 149A:1224-1230.
4. Saitsu H, Osaka H, Sugiyama S, Kurosawa K, Mizuguchi T, Nishiyama K, Nishimura A, Tsurusaki Y, Doi H, Miyake N, et al: Early infantile epileptic encephalopathy associated with the disrupted gene encoding Slit-Robo Rho GTPase activating protein 2 (SRGAP2). Am J Med Genet A 2012, 158A:199-205.
5. Morgulis A, Gertz EM, Schaffer AA, Agarwala R: WindowMasker: window-based masker for sequenced genomes. Bioinformatics 2006, 22:134-141.
6. Sone J, Mitsuhashi S, Fujita A, Mizuguchi T, Hamanaka K, Mori K, Koike H, Hashiguchi A, Takashima H, Sugiyama H, et al: Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nat Genet 2019, 51:1215-1221.
7. Hamada M, Ono Y, Asai K, Frith MC: Training alignment parameters for arbitrary sequencers with LAST-TRAIN. Bioinformatics 2017, 33:926-928.
8. Richardson SR, Doucet AJ, Kopera HC, Moldovan JB, Garcia-Perez JL, Moran JV: The Influence of LINE-1 and SINE Retrotransposons on Mammalian Genomes. Microbiol Spectr 2015, 3:MDNA3-0061-2014.
9. Scherer SW, Poorkaj P, Allen T, Kim J, Geshuri D, Nunes M, Soder S, Stephens K, Pagon RA, Patton MA, et al.: Fine mapping of the autosomal dominant split hand/split foot locus on chromosome 7, band q21.3-q22.1. Am J Hum Genet 1994, 55:12-20.
10. Crackower MA, Scherer SW, Rommens JM, Hui CC, Poorkaj P, Soder S, Cobben JM,

Hudgins L, Evans JP, Tsui LC: Characterization of the split hand/split foot malformation locus SHFM1 at 7q21.3-q22.1 and analysis of a candidate gene for its expression during limb development. Hum Mol Genet 1996, 5:571-579.
11. Marchi E, Kanapin A, Magiorkinis G, Belshaw R: Unfixed endogenous retroviral insertions in the human population. \(J\) Virol 2014, 88:9529-9537.
12. Ewing AD, Ballinger TJ, Earl D, Broad Institute Genome S, Analysis P, Platform, Harris CC, Ding L, Wilson RK, Haussler D: Retrotransposition of gene transcripts leads to structural variation in mammalian genomes. Genome Biol 2013, 14:R22.
13. Tsuji J, Frith MC, Tomii K, Horton P: Mammalian NUMT insertion is non-random. Nucleic Acids Res 2012, 40:9073-9088.
14. Ewing AD, Kazazian HH, Jr.: High-throughput sequencing reveals extensive variation in human-specific L1 content in individual human genomes. Genome Res 2010, 20:12621270.
15. Jain M, Koren S, Miga KH, Quick J, Rand AC, Sasani TA, Tyson JR, Beggs AD, Dilthey AT, Fiddes IT, et al: Nanopore sequencing and assembly of a human genome with ultralong reads. Nat Biotechnol2018, 36:338-345.
16. International HapMap C, Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, et al: Integrating common and rare genetic variation in diverse human populations. Nature 2010, 467:52-58.
17. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA: A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073.```

